Aproxi 125 mg (Capsule)

Indications

• Prevention of postoperative nausea and vomiting (PONV)
• Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)

Pharmacology

Aprepitant is a selective high affinity antagonist of human substance P neurokinin 1 (NK1) receptors.

Dosage

• Recommended oral dosage of Aprepitant is 40 mg within 3 hours prior to induction of anesthesia
• Specific regimen for prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy
• Specific regimen for prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy

Administration

Aprepitant may be taken with or without food.

Interaction

• Aproxi is a substrate, a weak-to-moderate (dose dependent) inhibitor, and an inducer of CYP3A4
• Precautions while coadministering Aproxi with drugs that use CYP3A4 or CYP2C9
• Reduced efficacy of hormonal contraceptives during and for 28 days following the last dose of Aproxi

Contraindications

Aprepitant is contraindicated in patients who are hypersensitive to any component of the product.

Side Effects

• Constipation
• Hypotension
• Pruritus
• Pyrexia

Pregnancy & Lactation

Pregnancy Category B. This drug should be used during pregnancy only if clearly needed.

Use in Special Populations

• No dosage adjustment is necessary for patients with renal impairment or for patients with end-stage renal disease (ESRD) undergoing hemodialysis
• No dosage adjustment is necessary for patients with mild to moderate hepatic impairment

Overdose Effects

• Drowsiness and headache due to overdose
• In the event of overdose, Aproxi should be discontinued
• General supportive treatment and monitoring should be provided
• Aproxi cannot be removed by hemodialysis

Therapeutic Class

Anti-emetic drugs

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Related Brands

• Emetant 40 mg (Capsule) - biogen-pharmaceuticals-ltd